Psychosis involves complex brain interactions, from neurotransmitter imbalances to genetic risks. Understanding its biology ...

MERIT is one of several metacognitive psychotherapies, designed especially to meet the needs of individuals living with serious mental illnesses, including schizophrenia. It is deliverable in both ...

When one discusses about their money with others, it often triggers feelings of insecurity or competition in others, as per psychology. Remember, not all who are your friends wish well for you.

A new, closely watched schizophrenia medication from Bristol Myers Squibb sold well in its first full quarter on the market, according to both the company and analysts. In its latest earnings report, ...

A Bristol Myers Squibb drug whose landmark FDA approval introduced the first novel mechanism for treating schizophrenia in decades has failed a pivotal test intended to support expanding its use ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported topline outcomes from the Phase III ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported topline outcomes from the Phase III ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

Bristol Myers Squibb’s schizophrenia drug Cobenfy failed to significantly ease symptom severity when used alongside atypical antipsychotics in patients with schizophrenia, according to a topline ...

Bristol Myers Squibb has shared results from its Phase III ARISE trial evaluating Cobenfy (xanomeline and trospium chloride) as an add on therapy to atypical antipsychotics in adults with inadequately ...